Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk

E. Cerquetani, C. Vitale, G. Mercuro, M. Fini, S. Zoncu, G. M C Rosano

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hormone replacement therapy (HRT) improves endothelial function in postmenopausal women while the effects of raloxifene, a selective estrogen receptor modulator, are still under debate. The aim of this study was to evaluate endothelium-dependent flow-mediated vasodilatation in the brachial artery and plasma levels of nitrite, nitrate and endothelin-1 in 20 postmenopausal women with increased cardiovascular risk treated with either HRT or raloxifene for 4 weeks in a randomized double-blind single cross-over study. Patients had an endothelium-dependent flow-mediated dilatation of 4% prior to initiation of the study. Treatment with HRT resulted in a 67% increase in dilatation compared with baseline (from a 7.4% increase to a 12.4% increase, p <0.01). Raloxifene treatment resulted in no change in vasodilatation from baseline. Endothelium-dependent dilatation was significantly improved by HRT compared with raloxifene treatment (12.4 ± 0.6% vs. 6.1 ± 2.0%; p <0.01). Compared with baseline values, nitrate plus nitrite levels increased significantly (p <0.05) with HRT but not with raloxifene. Similarly, endothelin-1 decreased from baseline with both treatments, but only the HRT-induced decrease was statistically significant (p <0.05). In conclusion, HRT improved endothelial function and reduced plasma levels of endothelin-1 in postmenopausal women at risk of coronary artery disease. These beneficial effects were not shared by raloxifene.

Original languageEnglish
Pages (from-to)291-298
Number of pages8
JournalGynecological Endocrinology
Volume18
Issue number6
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Hormone Replacement Therapy
Blood Vessels
Endothelin-1
Endothelium
Dilatation
Nitrites
Vasodilation
Nitrates
Selective Estrogen Receptor Modulators
Brachial Artery
Therapeutics
Raloxifene Hydrochloride
Cross-Over Studies
Coronary Artery Disease

Keywords

  • Cardiovascular Risk
  • HRT
  • Raloxifene
  • Vascular Effects

ASJC Scopus subject areas

  • Endocrinology
  • Obstetrics and Gynaecology

Cite this

Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk. / Cerquetani, E.; Vitale, C.; Mercuro, G.; Fini, M.; Zoncu, S.; Rosano, G. M C.

In: Gynecological Endocrinology, Vol. 18, No. 6, 06.2004, p. 291-298.

Research output: Contribution to journalArticle

@article{d35e60a31b7f46158cde09f684b0fd77,
title = "Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk",
abstract = "Hormone replacement therapy (HRT) improves endothelial function in postmenopausal women while the effects of raloxifene, a selective estrogen receptor modulator, are still under debate. The aim of this study was to evaluate endothelium-dependent flow-mediated vasodilatation in the brachial artery and plasma levels of nitrite, nitrate and endothelin-1 in 20 postmenopausal women with increased cardiovascular risk treated with either HRT or raloxifene for 4 weeks in a randomized double-blind single cross-over study. Patients had an endothelium-dependent flow-mediated dilatation of 4{\%} prior to initiation of the study. Treatment with HRT resulted in a 67{\%} increase in dilatation compared with baseline (from a 7.4{\%} increase to a 12.4{\%} increase, p <0.01). Raloxifene treatment resulted in no change in vasodilatation from baseline. Endothelium-dependent dilatation was significantly improved by HRT compared with raloxifene treatment (12.4 ± 0.6{\%} vs. 6.1 ± 2.0{\%}; p <0.01). Compared with baseline values, nitrate plus nitrite levels increased significantly (p <0.05) with HRT but not with raloxifene. Similarly, endothelin-1 decreased from baseline with both treatments, but only the HRT-induced decrease was statistically significant (p <0.05). In conclusion, HRT improved endothelial function and reduced plasma levels of endothelin-1 in postmenopausal women at risk of coronary artery disease. These beneficial effects were not shared by raloxifene.",
keywords = "Cardiovascular Risk, HRT, Raloxifene, Vascular Effects",
author = "E. Cerquetani and C. Vitale and G. Mercuro and M. Fini and S. Zoncu and Rosano, {G. M C}",
year = "2004",
month = "6",
doi = "10.1080/09513590410001729888",
language = "English",
volume = "18",
pages = "291--298",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk

AU - Cerquetani, E.

AU - Vitale, C.

AU - Mercuro, G.

AU - Fini, M.

AU - Zoncu, S.

AU - Rosano, G. M C

PY - 2004/6

Y1 - 2004/6

N2 - Hormone replacement therapy (HRT) improves endothelial function in postmenopausal women while the effects of raloxifene, a selective estrogen receptor modulator, are still under debate. The aim of this study was to evaluate endothelium-dependent flow-mediated vasodilatation in the brachial artery and plasma levels of nitrite, nitrate and endothelin-1 in 20 postmenopausal women with increased cardiovascular risk treated with either HRT or raloxifene for 4 weeks in a randomized double-blind single cross-over study. Patients had an endothelium-dependent flow-mediated dilatation of 4% prior to initiation of the study. Treatment with HRT resulted in a 67% increase in dilatation compared with baseline (from a 7.4% increase to a 12.4% increase, p <0.01). Raloxifene treatment resulted in no change in vasodilatation from baseline. Endothelium-dependent dilatation was significantly improved by HRT compared with raloxifene treatment (12.4 ± 0.6% vs. 6.1 ± 2.0%; p <0.01). Compared with baseline values, nitrate plus nitrite levels increased significantly (p <0.05) with HRT but not with raloxifene. Similarly, endothelin-1 decreased from baseline with both treatments, but only the HRT-induced decrease was statistically significant (p <0.05). In conclusion, HRT improved endothelial function and reduced plasma levels of endothelin-1 in postmenopausal women at risk of coronary artery disease. These beneficial effects were not shared by raloxifene.

AB - Hormone replacement therapy (HRT) improves endothelial function in postmenopausal women while the effects of raloxifene, a selective estrogen receptor modulator, are still under debate. The aim of this study was to evaluate endothelium-dependent flow-mediated vasodilatation in the brachial artery and plasma levels of nitrite, nitrate and endothelin-1 in 20 postmenopausal women with increased cardiovascular risk treated with either HRT or raloxifene for 4 weeks in a randomized double-blind single cross-over study. Patients had an endothelium-dependent flow-mediated dilatation of 4% prior to initiation of the study. Treatment with HRT resulted in a 67% increase in dilatation compared with baseline (from a 7.4% increase to a 12.4% increase, p <0.01). Raloxifene treatment resulted in no change in vasodilatation from baseline. Endothelium-dependent dilatation was significantly improved by HRT compared with raloxifene treatment (12.4 ± 0.6% vs. 6.1 ± 2.0%; p <0.01). Compared with baseline values, nitrate plus nitrite levels increased significantly (p <0.05) with HRT but not with raloxifene. Similarly, endothelin-1 decreased from baseline with both treatments, but only the HRT-induced decrease was statistically significant (p <0.05). In conclusion, HRT improved endothelial function and reduced plasma levels of endothelin-1 in postmenopausal women at risk of coronary artery disease. These beneficial effects were not shared by raloxifene.

KW - Cardiovascular Risk

KW - HRT

KW - Raloxifene

KW - Vascular Effects

UR - http://www.scopus.com/inward/record.url?scp=3142689131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142689131&partnerID=8YFLogxK

U2 - 10.1080/09513590410001729888

DO - 10.1080/09513590410001729888

M3 - Article

C2 - 15497491

AN - SCOPUS:3142689131

VL - 18

SP - 291

EP - 298

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 6

ER -